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Abstract
Objective: To investigate the comparative efficacy and safety of the low-dose versus 
standard-dose alteplase using real-world acute stroke registry data from Asian countries.
Methods: Individual participant data were obtained from 9 acute stroke registries from 
China, Japan, Philippines, Singapore, South Korea and Taiwan between 2005 and 2018.  
Inverse probability of treatment weight was used to remove baseline imbalances between 
those receiving low-dose vs standard-dose alteplase.  The primary outcome was death or 
disability defined by modified Rankin Scale (mRS) scores of 2-6 at 90 days.  Secondary 
outcomes were symptomatic intracerebral hemorrhage (sICH) and death.  Generalized linear 
mixed models with the individual registry as a random intercept were performed to determine 
associations of treatment with low-dose alteplase and outcomes.
Results: Of the 6250 patients (mean age 66 years, 36% women) included in these analyses, 
1610 (24%) were treated with low-dose iv alteplase.  Clinical outcomes for low-dose 
alteplase were not significantly different to those for standard-dose alteplase, adjusted odds 
ratios for death or disability: 1.00 (0.85-1.19) and sICH 0.87 (0.63-1.19), except for lower 
death with borderline significance, 0.77 (0.59-1.01).
Conclusions: The present analyses of real-world Asian acute stroke registry data suggest that 
low-dose iv alteplase has overall comparable efficacy for functional recovery and greater 
potential safety in terms of reduced mortality, to standard-dose alteplase for the treatment of 
acute ischemic stroke.
Key words- acute ischemic stroke; thrombolysis; alteplase dose; symptomatic intracranial 
hemorrhage; individual patient analysis; Asian
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Introduction
Recombinant tissue plasminogen activator (rtPA/alteplase) is the established treatment for 
acute ischemic stroke (AIS).  Most guidelines1, 2 recommend an intravenous (iv) dose of 0.9 
mg/kg of alteplase (10% as a bolus and the remaining as an infusion over 1-hour; maximum 
dose 90mg) to eligible patients with AIS, presenting within 3 or 4.5 hours of symptom-onset, 
based on the National Institute of Neurological Disorders and Stroke (NINDS)3 and the 
European Cooperative Acute Stroke Study (ECASS) trials,4-6 respectively.  However, a dose 
of 0.6 mg/kg (10% as a bolus and the remaining as an infusion over 1 hour; maximum dose 
60mg) is the approved dose of alteplase in Japan7, where non-randomized studies8-11 have 
suggested comparable clinical outcomes and reduced risk of symptomatic intracerebral 
hemorrhage (sICH) compared to the standard-dose.8, 9  In other Asian countries, low-dose 
alteplase is used widely, largely due to the reduced cost and anticipated lower rates of 
sICH.12, 13
The ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED)13-
15 has been the only randomized comparison of low- versus standard-dose iv alteplase in AIS 
patients who fulfilled standard eligibility criteria for this treatment.  The study demonstrated 
that low-dose alteplase did not meet the stringent non-inferiority criteria compared to 
standard-dose alteplase with respect to the conventional binary clinical endpoint of death and 
disability, defined by scores of 2-6 on the modified Rankin scale (mRS) at 90 days.  
However, low-dose alteplase was non-inferior with respect to an ordinal analysis of this 
endpoint, and there were significantly fewer cases of sICH across all standard criteria in the 
low-dose alteplase group.  The ENCHANTED results have stimulated debate about the 
widespread use of low-dose alteplase in Asian medical practice.
Systematic reviews16, 17 comparing low- and standard-dose alteplase have shown little 
difference in clinical outcomes, possibly due to individual studies being under-powered.  
Page 5 of 18 International Journal of Stroke
For Review Only
5
Hence, we initiated an international collaborative, individual patient data (IPD) pooling 
project, to compare low- and standard-dose alteplase, with the aim of providing reliable 
evidence about the optimal dose of iv alteplase for Asian AIS patients.
METHODS
This study was based on IPD and adhered to the PRISMA-IPD (Preferred Reporting Items for 
a Systematic Review and Meta-analysis of Individual Participant Data).18  All participating 
studies were approved by their local ethics committees.  Data were obtained from 9 stroke 
registries from 6 Asian countries (China, Japan, Philippines, Singapore, South Korea and 
Taiwan), 6 of which were identified by a systematic search, representing 50% of the 12 
potentially eligible studies with sample size over 100;19 3 were unpublished.  We requested 
de-identified IPD on patient characteristics, the dose of alteplase and outcomes from the 
study investigators.  The reasons for excluding 6 studies were ethical approval not being 
granted (4) and refusal to participate (2) (Supplementary table 1).
We collected information on factors that might explain the differences in the association 
between alteplase-dose treatment and outcomes including: (i) alteplase treatment (time from 
onset to treatment and dosage); (ii) demographics (age, sex, body weight, country of 
recruitment); (iii) medical history (hypertension, previous stroke, coronary artery disease, 
atrial fibrillation, diabetes, hypercholesterolemia and smoking); (iv) medication history 
(antihypertensive medication, lipid-lowering medication, antidiabetic medication, warfarin 
use, aspirin or other antiplatelet use); (v) hemodynamic parameters (systolic/diastolic blood 
pressure, heart rate); and (vi) stroke severity (the National Institute of Health Stroke Scale 
[NIHSS]) and stroke etiology according to the Trial of Org 10172 in acute stroke treatment 
(TOAST) classification20.
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Functional outcome was measured by mRS at 3 months.  The definition of sICH varied 
among the studies: 3 studies defined it as per the NINDS trial3, 5 studies defined it as 
radiological evidence of ICH associated with neurological deterioration (4 used a 
corresponding 4-points increase on the NIHSS; 1 study used a 2-point increase), and 1 study 
defined it as per the ECASS II5 trial (any ICH with neurological deterioration [>4 points on 
the NIHSS) from baseline or death within 24 to 36 hours) (Supplementary table 2).
Data not provided in the article because of space limitations may be shared (anonymized) at 
the request of any qualified investigator for purposes of replicating procedures and results.
Statistical analysis
Initial internal analyses were performed to compare baseline and outcome data from each 
study with their published results to ensure that data were complete and transferred without 
error.  Since most of the individual study results have already been published, results from 
analysis of individual studies will not be identifiable in this publication.  We, therefore, used 
the 1-stage method of analysis proposed for IPD meta-analyses.
The characteristics of the low-dose alteplase group were expected to substantially differ from 
those of the standard-dose group.  To generate a comparable data set, we calculated a 
propensity score to estimate the individual probability of a patient receiving low-dose 
alteplase.  Six variables were used as covariates to calculate propensity scores (sex, age, 
baseline systolic blood pressure [SBP], baseline NIHSS, premorbid mRS, time from onset to 
treatment, and presence of vascular risk factors [prior transient ischemic stroke, stroke, 
hypertension, coronary artery disease, atrial fibrillation, diabetes or hypercholesterolemia]).  
The inverse probability of treatment weighting (IPTW) was used as the primary strategy to 
adjust for baseline imbalances.21  Data balancing was examined using an absolute 
standardized difference in covariate means.22  The distributions of baseline covariates were 
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fairly well balanced by applying propensity scores; the absolute standardized differences after 
IPTW were within an acceptable margin of 0.1 (supplementary figure 1).  Stabilized 
weights23 were used to reduce variance of the estimated effect of low-dose alteplase, and 
were incorporated into generalized linear mixed models with the individual registry as a 
random intercept to determine associations of treatment with low/standard-dose alteplase and 
outcomes.
For all analyses involving the primary outcome of functional recovery (ordinal scores on the 
mRS), we checked the proportional odds assumption was not violated; where this was violated, 
we present functional outc me according to binary mRS scores.  Subgroup analyses by key 
demographic variables (sex; age <65 vs. ≥65 years), clinical severity (defined by NIHSS scores 
<10 vs. ≥10 points), treatment (time from onset to treatment <3 vs. ≥3 hours), TOAST 
classification (large-artery atherosclerosis, small-vessel, cardioembolism, and other etiology) 
and premorbid mRS (0-1 vs. 2-5)were undertaken to test the consistency of any association.  
We assessed the heterogeneity of association in subgroups by adding an interaction term in the 
models.  Data are presented as odds ratios (OR) and 95% confidence intervals (CI).  A two 
sided P <0.05 was set as the level for statistical significance.  All statistical analyses were 
performed using SAS version 9.3 (SAS institute, Cary, NC, USA).
Results
There were 6852 patients from 8 studies, 6250 of which were treated either by low-dose 
alteplase (0.55-0.65 mg/kg, 23.4%) or standard-dose alteplase (0.85-0.95 mg/kg, 66.6%).  
Data for sICH were available in all patients, mRS data in 4055, and sICH data in 6250 
patients.  The mean age of the patients was 66 years, 37% were female, and the median 
NIHSS was 10 (IQR 6-16).  Table 1 shows the baseline characteristics of patients according 
to alteplase dosage: those in the low-dose group were significantly older and more 
neurologically impaired, and a higher proportion were female, hypertensive, and with co-
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morbidity.  Additionally, strokes due to large-artery atherosclerosis were more likely to be 
treated with standard-dose alteplase, while strokes due to cardioembolism were more likely to 
be treated with low-dose alteplase.
The distribution of mRS scores at 3 months was shown in figure 1.  Compared to standard-
dose alteplase, treatment with low-dose alteplase was not associated with death and disability 
(mRS 2-6) at 3 months (OR 1.00, CI 0.85-1.19) or sICH (OR 0.87, CI 0.63-1.19)  (Figure 2).  
However, treatment with low-dose alteplase was associated with lower risk of 3-month 
mortality with borderline significance (OR 0.77, CI 0.59-1.01).
Figure 3 shows that associations were consistent across the key subgroups by age, sex, stroke 
severity,time from onset to treatment, and stroke subtype.  Although, significant 
heterogeneity was evident for dichomtised  premorbid mRS (0-1 vs. 2-5), the current study is 
under-powered to explore the association for the subgroup of premorbid mRS 2-5.
DISCUSSION
This IPD meta-analysis aimed to provide reliable evidence about the efficacy and safety of 
low-dose alteplase in real world Asian populations, adjusted for important confounders.  Our 
analyses of pooled data from 9 real-world acute stroke registries from Asian countries show 
that low-dose alteplase treatment of AIS has comparable overall efficacy and potentially 
improved safety compared with standard-dose alteplase when used to treat AIS within 4.5 
hours of onset.
We confirm findings from previous comprehensive systematic reviews that show low- and 
standard-dose alteplase have equivalent outcomes for the treatment of AIS.12, 19  In the 
present study, 63% of patients who were treated with low-dose alteplase had the outcome of 
death or disability (mRS 2-6), which is similar to the single-arm nonrandomized studies first 
and second Japan Alteplase Clinical Trial (J-ACT 1 and 2), and the Japan Post-marketing 
Page 9 of 18 International Journal of Stroke
For Review Only
9
Alteplase Registration Study (JMARS).  Additionally, 55% of patients treated with standard-
dose alteplase had the outcome of death or disability, which is comparable to data from the 
multinational Safe Implementation of Thrombolysis in Stroke–Non-European Union World 
study,24 NINDS trial,3 and the Safe Implementation of Thrombolysis in Stroke-Monitoring 
Study (SITS-MOST).25  These similarities support the reliability of our large dataset of 
pooled real-world IPD.
In regard to functional outcome at 90 days, we found that for those treated with low-dose 
alteplase, a smaller proportion of deaths was accompanied by an increase in moderate to 
severe disability amongst survivors – a finding that is consistent with that of the 
ENCHANTED trial.  This finding occurred despite differences in patient characteristics at 
baseline; patients enrolled in ENCHANTED were younger, had milder deficits, were treated 
with alteplase at a longer time from the onset of symptoms, and were less likely to have atrial 
fibrillation or major arterial occlusion.  These factors may be considered barriers to 
implementation of the ENCHANTED findings directly into clinical practice, however our 
real-world data provide support for the generalizability of these trial results.
A notable point of difference relates to alteplase dose and sICH risk; the ENCHANTED trial 
showed that low-dose alteplase significantly reduced the risk of sICH, however our analyses 
showed no such association.  This discordance could be explained by differences between the 
definitions used to identify sICH in a clinical trial and across real-world clinical practice in 
several different healthcare systems; it may also be explained by inadequate adjustment for 
confounders.  For example, we did not have information on prior antiplatelet or anticoagulant 
use, both of which are important prognostic factors in thrombolysis-associated ICH.  Another 
limitation of the present study is data availability bias arising from our inability to acquire 
IPD from 4 large registries in Japan and Taiwan (8840 patients) due to ethical approval 
issues.  In addition, there is significant difference in time from onset to treatment and 
Page 10 of 18International Journal of Stroke
For Review Only
10
countries contributing standard and low-dose alteplase patients which may have affected our 
overall results.  However higher age, higher NIHSS are points against for low-dose alteplase, 
which may have nullified effects though we have conducted propensity score matching 
analysis.
Prior to this work, observational studies from Asia reported conflicting findings.  For 
instance, low-dose alteplase was found to be equivalent to standard-dose in a large 
observational registry from South Korea.26  Conversely, the Thrombolysis Implementation 
and Monitor of Acute Ischemic Stroke registry in China showed that standard-dose alteplase 
produced favorable outcomes without increasing the risk of sICH.27  Therefore, our analyses 
of pooled IPD, which include the aforementioned studies, provide clarity in producing a 
comprehensive summary of the evidence, and greater power to detect meaningful 
associations between alteplase dose and outcome, adjusted for important confounders.
In summary, this international collaborative project, curated and analyzed IPD from a wide 
variety of Asian stroke registry studies, reports that low- and standard-dose alteplase have 
equivalent outcomes in AIS.  This finding needs to confirmed in a randomised clinical trial 
including patients undergoing mechanical thrombectomy as well.
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Figure legends
Figure 1: mRS distribution by low-dose versus standard-dose alteplase
Figure 2: Association between low-dose and standard-dose alteplase and clinical outcomes
Model a: propensity score was derived from the model with sex, age, baseline NIHSS, time 
from onset to treatment, and risk factor (prior TIA, stroke, hypertension, coronary artery 
disease, AF, diabetes, or hypercholesterolemia]
Model b: propensity score was derived from the model with sex, age, baseline NIHSS score, 
premorbid modified Rankin Scale(mRS), time from onset to treatment, and risk factor (prior 
TIA, stroke, hypertension, coronary artery disease, AF, diabetes, or hypercholesterolemia]
Figure 3 subgroup analysis
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Table 1. Baseline characteristics
Standard-dose alteplase 
(0.9 mg/kg) (n=4640)
Low-dose alteplase 
(0.6 mg/kg) (n=1610)
P value
Age, mean (SD) 65.1(12.0) 68.4(12.9) <0.0001
Female 1640/4598(35.7) 604/1548(39.0) 0.018
Time from stroke onset to treatment, median(IQR) 2.52(1.83-3.08) 2.30(1.75-2.83) <0.0001
Country <0.0001
    China 2877/4640(62.0) 347/1610(21.6)
    Korea 1076/4640(23.2) 450/1610(28.0)
    Japan 0(0.00) 600/1610(37.3)
    Taiwan 368/4640(7.9) 22/1610(1.4)
    Singapore 224/4640(4.8) 135/1610(8.4)
    Philippines 95/4640(2.1) 56/1610(3.5)
NIHSS, median(IQR) 9(5-15) 11(6-18) <0.0001
SBP 148.6(24.9) 151.1(23.6) 0.0002
DBP 86.2(14.9) 84.3(16.0) <0.0001
Pre-morbid mRS <0.0001
    0-1 2610/4117(63.4) 1100/1413(77.9)
    2-5 1507/4117(36.6) 313/1413(22.2)
Smoking 1662/4512(36.8) 368/1007(36.5) 0.863
Prior stroke 657/3545(18.5) 237/1149(20.6) 0.116
Prior coronary artery disease 104/2281(4.6) 160/944(17.0) <0.0001
Prior atrial fibrillation 1097/4640(23.6) 606/1600(37.9) <0.0001
Prior hypertension 2961/4640(63.8) 1068/1606(66.5) 0.053
Prior dislipidemia 853/4638(18.4) 438/1603(27.3) <0.0001
Prior diabetes mellitus 1046/4640(22.5) 383/1609(23.8) 0.300
TOAST classification <0.0001
    Large-artery atherosclerosis 854/2287(37.3) 369/1475(25.0)
    Small-vessel occlusion 243/2287(10.6) 143/1475(9.7)
    Cardioembolism 678/2287(29.7) 694/1475(47.1)
    Others 512/2287(22.4) 269/1475(18.2)
SD: standard deviation; IQR: interquartile range; mRS: modified Rankin Scale; TOAST: Aetiological Trial of 
Org 10172 in acute stroke treatment (TOAST) classification  
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Figure 3
Sex
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